Evidence map›Paper›PMID 34820407›Full record

ArticleFrontiers in medicine2021

Increased Levels of sCD30 Have No Impact on the Incidence of Early ABMR and Long-Term Outcome in Intermediate-Risk Renal Transplant Patients With Preformed DSA.

Thomas Drasch, Christian Bach, Markus Luber, Bernd Spriewald, Kirsten Utpatel, Maike Büttner-Herold, Bernhard Banas, Daniel Zecher

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Thomas DraschDepartment of Nephrology, University Hospital Regensburg, Regensburg, Germany.
Christian BachDepartment of Internal Medicine 5-Hematology and Oncology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.
Markus LuberDepartment of Internal Medicine 5-Hematology and Oncology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.
Bernd SpriewaldDepartment of Internal Medicine 5-Hematology and Oncology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.
Kirsten UtpatelInstitute of Pathology, Regensburg University, Regensburg, Germany.
Maike Büttner-HeroldDepartment of Nephropathology, University Hospital Erlangen, Erlangen, Germany.
Bernhard BanasDepartment of Nephrology, University Hospital Regensburg, Regensburg, Germany.
Daniel ZecherDepartment of Nephrology, University Hospital Regensburg, Regensburg, Germany.
University Hospital Regensburg · DEFriedrich-Alexander-Universität Erlangen-Nürnberg · DEUniversitätsklinikum Erlangen · DEUniversity of Regensburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ABMRantibody-mediated rejectiondonor-specific anti HLA antibodieskidney transplantationrisk stratificationsCD30

Identifiers

PMID34820407
PMCPMC8606593
OpenAlexW3211666768

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.